{"id":1672,"date":"2024-08-05T21:40:00","date_gmt":"2024-08-06T02:40:00","guid":{"rendered":"https:\/\/gaffel.mixture.com.co\/?p=1672"},"modified":"2025-07-07T13:15:23","modified_gmt":"2025-07-07T18:15:23","slug":"la-necesidad-insatisfecha-de-nuevos-medicamentos-contra-el-insomnio","status":"publish","type":"post","link":"https:\/\/gaffel.mixture.com.co\/en\/blog\/la-necesidad-insatisfecha-de-nuevos-medicamentos-contra-el-insomnio\/","title":{"rendered":"The unmet need for new drugs against insomnia."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Benzodiazepines or Z-drugs (such as zolpidem, zopiclone, and eszopiclone) have dominated the market for pharmacological treatments for insomnia for the past 30 years, but due to their unfavorable side effect profile, additional treatment options are needed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There are currently four Phase 3 products in development for the treatment of insomnia. However, they do not have novel mechanisms of action that differentiate them from marketed products. The approval of dual orexin receptor antagonists (Suvorexant, lemborexant and daridorexant) for the treatment of insomnia, which selectively inhibit arousal and promote sleep, offer a superior safety profile compared to Z-drugs. Unlike Z-drugs, discontinuation of DORA (dual orexin receptor antagonists) treatment is not associated with rebound insomnia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There are a limited number of late-stage agents for insomnia, with only four products in Phase 3 development: Vanda Pharmaceuticals' Hetlioz (tasimelteon), EUSOL Biotech's SM-1 (diphenhydramine + lorazepam + zolpidem), Taisho Pharmaceutical's vornorexant, and Johnson &amp; Johnson's seltorexant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hetlioz (tasimelteon) is an FDA-approved melatonin agonist for two rare sleep disorders: non-24-hour sleep\/wake disorder and Smith-Magenis syndrome. But Vanda Pharmaceuticals is looking to expand its labels and plans to file a supplemental new drug application for the treatment of insomnia in 2024. This would allow the drug to compete with marketed melatonin receptor agonists, including Takeda\u2019s Rozerem (ramelteon) and its generic versions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Taisho\u2019s vornorexant could be the next DORA to enter the market, competing with Merck\u2019s Belsomra (suvorexant), Eisai\u2019s Dayvigo (lemborexant), and Idorsia\u2019s Quviviq (daridorexant). Unlike DORAs, which target both the orexin type 1 and type 2 receptors, Johnson and Johnson\u2019s seltorexant selectively antagonizes the orexin type 2 receptor and is being investigated as an add-on therapy to antidepressants for patients with major depressive disorder and insomnia symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read interesting news like this in our Gaffel News Magazine:\u00a0<a href=\"https:\/\/www.flipsnack.com\/CCA6559BDC9\/gaffel-news-edici-n-22-marzo-2024\/full-view.html\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">https:\/\/www.flipsnack.com\/CCA6559BDC9\/gaffel-news-edici-n-22-marzo-2024\/full-view.html<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source:\u00a0<a href=\"https:\/\/www.google.com\/url?sa=E&amp;q=https%3A%2F%2Fsleepreviewmag.com%2Fsleep-disorders%2Finsomnia%2Funmet-need-new-insomnia-drugs%2F\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">https:\/\/sleepreviewmag.com\/sleep-disorders\/insomnia\/unmet-need-new-insomnia-drugs\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>\ud83c\udf19\ud83d\udc8a Every night, millions of people struggle to find restful sleep. In a world where treatment options for insomnia have been limited and come with unwanted side effects, the need for new alternatives is more urgent than ever and challenges us to find more effective and safer solutions. How can we improve the quality of sleep and the lives of those who suffer from it? \ud83d\ude34 Here, we explore the unmet need for new insomnia medications. From advances in dual orexin receptor antagonists to products in late-stage development, there is hope on the horizon.<\/p>","protected":false},"author":1,"featured_media":1673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_joinchat":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/1672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/comments?post=1672"}],"version-history":[{"count":1,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/1672\/revisions"}],"predecessor-version":[{"id":1674,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/1672\/revisions\/1674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/media\/1673"}],"wp:attachment":[{"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/media?parent=1672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/categories?post=1672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gaffel.mixture.com.co\/en\/wp-json\/wp\/v2\/tags?post=1672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}